Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.

CONCLUSION: Eribulin-trastuzumab combination is an effective and safe treatment option with a low toxicity profile for aggressively pre-treated patients with metastatic breast cancer. PMID: 33455097 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research